The Online Investor
Drugs & Pharmaceuticals M&A image Drugs & Pharmaceuticals M&A » By The Online Investor Staff, updated Fri., Dec. 3, 4:34 PM Recent mergers and acquisitions in the Drugs & Pharmaceuticals M&A category.

Slide #99. OPKO Health, Inc. PROLOR Biotech, Inc.

Acquirer: OPKO Health, Inc. (OPK)
Acquiree: PROLOR Biotech, Inc. (PBTH)
Details: OPKO Health, Inc. (NYSE: OPK) and PROLOR Biotech, Inc. (NYSE MKT: PBTH) today announced that the companies have signed a definitive merger agreement under which OPKO will acquire PROLOR, a biopharmaceutical company focused on developing and commercializing longer-acting proprietary versions of already approved therapeutic proteins, in an all-stock transaction. Under the terms of the agreement, which has been approved by the boards of directors of both companies, holders of PROLOR common stock will receive 0.9951 shares of OPKO common stock for each share of PROLOR common stock. Based on a price of $7.03 per share of OPKO common stock, the transaction is valued at approximately $480 million, or $7.00 per share of PROLOR common stock. The companies expect the transaction to be completed during the second half of 2013. Closing of the transaction is subject to certain conditions including, the approval of OPKO's and PROLOR's stockholders and other customary closing conditions.

Opko Health is a healthcare company. Co.'s segments are diagnostics and pharmaceutical. Co.'s diagnostics segment provides laboratory testing services utilized by healthcare providers in the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health and correctional healthcare. Co.'s pharmaceutical business features Rayaldee, a treatment for secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease and vitamin D insufficiency; OPK88004, a selective androgen receptor modulator; and OPK88003, a once weekly oxyntomodulin for type 2 diabetes and obesity.

OPK SEC Filing Email Alerts Service


Open the OPK Page at The Online Investor »

Opko Health is a healthcare company. Co.'s segments are diagnostics and pharmaceutical. Co.'s diagnostics segment provides laboratory testing services utilized by healthcare providers in the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health and correctional healthcare. Co.'s pharmaceutical business features Rayaldee, a treatment for secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease and vitamin D insufficiency; OPK88004, a selective androgen receptor modulator; and OPK88003, a once weekly oxyntomodulin for type 2 diabetes and obesity.

OPK SEC Filing Email Alerts Service


Open the PBTH Page at The Online Investor »

Company Name: 
OPKO Health Inc
Website: 
www.opko.com
Sector: 
Drugs & Pharmaceuticals
Number of ETFs Holding OPK: 
36
Total Market Value Held by ETFs: 
$262.02M
Total Market Capitalization: 
$2.68B
% of Market Cap. Held by ETFs: 
9.78%
Company Name: 
PROLOR Biotech, Inc.
Website: 
www.prolor-biotech.com
Sector: 
Biotechnology
 

Quotes delayed 20 minutes

Email EnvelopeFree Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Drugs & Pharmaceuticals M&A - Slide 99 of 100 Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2021, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.